<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03930992</url>
  </required_header>
  <id_info>
    <org_study_id>OSZCO</org_study_id>
    <nct_id>NCT03930992</nct_id>
  </id_info>
  <brief_title>Efficacy of Zoledronic Acid + Colaren vs Zoledronic Acid + Conventional Treatment for Osteoporosis in HIV+ and HIV- Men</brief_title>
  <acronym>OSZCO</acronym>
  <official_title>Efficacy of 4 mg Zoledronic Acid Plus Colaren vs 4mg Zoledronic Acid + Conventional Treatment for Secondary Osteoporosis in HIV Positive and Negative Men</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Guadalajara</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital Civil de Guadalajara</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Guadalajara</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinical trial to assess the effectiveness of the supplement Colaren® associated with
      zoledronic acid 4mg/annually in the treatment of osteoporosis secondary, compared to standard
      treatment plus zoledronic acid 4mg/annually. The standard treatment will include 1gr of
      calcium/day and vitamin D supplement. In both cases, vitamin D levels will be determinated,
      which should remain at more than 30 ng/mL.

      Including men with osteoporosis secondary to HIV and men with osteoporosis secondary to any
      other cause (HIV negative). Vitamin D levels, bone densitometry and markers of metabolism,
      bone formation and bone resorption will be assessment. The all parameters above will be
      assessed basally (before the start of treatment), after starting the treatment, an assessment
      will be made at 12 weeks where vitamin D levels and bone markers will be measured. Meanwhile,
      at week 24 assess only vitamin D levels; and finally, at week 52 all parameters mentioned
      above will be measured.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a clinical trial to assess the effectiveness of the supplement Colaren®
      associated with annually zoledronic acid 4mg, in the treatment of osteoporosis secondary or
      not to HIV infection, compared to standard treatment plus zoledronic acid 4mg/annually. The
      standard treatment will include 1gr of calcium/day and vitamin D supplement. In both cases,
      vitamin D levels will be evaluated, which should remain at more than 30 ng/mL.

      Including men with osteoporosis secondary to HIV and men with osteoporosis secondary to any
      other cause (HIV negative). Vitamin D levels, bone densitometry and markers of metabolism,
      bone formation and bone resorption will be assessment. The all parameters above will be
      assessed basally (before the start of treatment), after starting the treatment, an assessment
      will be made at 12 weeks where vitamin D levels and bone markers will be measured. Meanwhile,
      at week 24 assess only vitamin D levels; and finally, at week 52 all parameters mentioned
      above will be measured.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 17, 2019</start_date>
  <completion_date type="Anticipated">February 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Study type: Interventional, with four arms:
arm: 4 mg zoledronic acid annually plus colaren ® in HIV-positive;
arm: 4 mg zoledronic acid annually plus conventional treatment in HIV-positive;
arm: 4 mg zoledronic acid annually plus colaren ® in HIV-negative;
arm: 4 mg zoledronic acid annually plus conventional treatment in HIV-negative.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Bone turnover markers (from baseline to 12 months under treatment)</measure>
    <time_frame>Time frame: from baseline, 3 and 12 months under treatment.</time_frame>
    <description>Plasma measure of (through LEGENDplex (Multiplex)):
Bone formation panel that include: Osteoprotegerin (OPG) measure in pg/mL, Alkaline Phosphatase Liver/Bone/Kidney (ALPL) measure in pg/mL, LEPTINA measure in pg/mL and Bone Morphogenetic Protein 2 (BMP-2) measure in pg/mL. Bone resorption panel that include: Osteopontin (OPN) measure in pg/mL, Acid Phosphatase 5 Tartrate Resistant (ACP5) measure in pg/mL, RANKL measure in pg/mL, Tumor Necrosis Factor Alpha (TNF-α) measure in pg/mL, Interleukin 6 (IL-6) measure in pg/mL, Parathyroid Hormone (PTH) measure in pg/mL, Interleukin 1 beta (IL-1β) measure in pg/mL, Dickkopf WNT Signaling Pathway Inhibitor 1 (DKK-1) measure in pg/mL.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline of Bone mineral density at 12 months</measure>
    <time_frame>Time frame: from baseline and 12 months under treatment.</time_frame>
    <description>Bone mineral density through Dual-energy X-ray absorptiometry (DXA scan) measure.
Classification:
Normal: T-score ≥ −1.0 Osteopenia: −2.5 &lt; T-score &lt; −1.0 Osteoporosis: T-score ≤ −2.5 Severe osteoporosis: T-score ≤ −2.5 with fragility fracture</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tolerability of colaren vs standard treatment (conventional treatment): grading the severity of Adult and Pediatric Adverse Events Version 2.0</measure>
    <time_frame>Time frame: evaluate the tolerability from month 1, 3, 6, 9 and 12, under supplementation</time_frame>
    <description>Evaluation of tolerability of Colaren and conventional treatment through the &quot;Division of AIDS table for grading the severity of Adult and Pediatric Adverse Events Version 2.0, November 2014&quot; Grade 1= Mild Grade 2= Moderate Grade 3= Severe Grade 4= Potentially</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">1</enrollment>
  <condition>Secondary Osteoporosis</condition>
  <arm_group>
    <arm_group_label>1 Arm: Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental: 4 mg zoledronic acid plus colaren ® This arm include: 20 man with HIV infection plus osteoporosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 Arm: Active comparator</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active comparator: 4mg zoledronic acid + standard treatment (or conventional treatment) This arm include: 20 man with HIV infection plus osteoporosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3 Arm: Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental: 4 mg zoledronic acid plus colaren ® This arm include: 20 man without HIV infection plus osteoporosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4 Arm: Active comparator</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active comparator: 4mg zoledronic acid + standard treatment (or conventional treatment) This arm include: 20 man without HIV infection plus osteoporosis</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colaren in HIV positive</intervention_name>
    <description>1 Arm (HIV+): will receive Zoledronic acid 4mg and colaren ® (vitamin D, magnesium, phosphate, calcium).</description>
    <arm_group_label>1 Arm: Experimental</arm_group_label>
    <other_name>plus Zoledronic Acid 4 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>standard treatment in HIV positive</intervention_name>
    <description>2 Arm (HIV+): will receive Zoledronic acid 4mg and standard treatment (vitamin D and calcium carbonate)</description>
    <arm_group_label>2 Arm: Active comparator</arm_group_label>
    <other_name>plus Zoledronic Acid 4 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colaren in HIV negative</intervention_name>
    <description>3 Arm (HIV-): will receive Zoledronic acid 4mg and colaren ® (vitamin D, magnesium, phosphate, calcium).</description>
    <arm_group_label>3 Arm: Experimental</arm_group_label>
    <other_name>plus Zoledronic Acid 4 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>standard treatment in HIV negative</intervention_name>
    <description>4 Arm (HIV-): will receive Zoledronic acid 4mg and standard treatment (vitamin D and calcium carbonate)</description>
    <arm_group_label>4 Arm: Active comparator</arm_group_label>
    <other_name>plus Zoledronic Acid 4 mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult males 18 to 65 years old.

          -  HIV diagnosis (HIV positive group) or negative HIV serology (HIV negative group).

          -  Patients receiving HAART and sustained virologic control for at least two years.

          -  Patients meeting diagnostic criteria for osteoporosis.

          -  Subjects willing to participate voluntarily in this study and give a written consent.

          -  Estimated glomerular filtration rate &gt;60 mL/min (Using CKD-EPI formula).

        Exclusion Criteria:

          -  Use of calcium, vitamin D or any other drug with bone activity during the last 90 days
             previous to the study.

          -  Use of herbs or herb products during the last 90 days previous to the study.

          -  Positive test for HCV or HBV.

          -  Patients who cannot be submitted to complete examination for variable analysis.

          -  Glomerular filtration rate &lt;60 mL/minute.

          -  Active liver disease.

          -  Non-compliance to treatment (less than 90%).

          -  Patients who are not willing to continue participating.

        Non-inclusion criteria:

          -  Female patients.

          -  Use of immunosuppressive o immunomodulatory treatment 90 days previous to selection.

          -  Use of prohibited drugs for the study like: antiestrogens, corticosteroids (doses
             greater than 7.5mg of prednisone/day) 90 days previous to selection.

          -  Use of hormone therapy.

          -  Patients with history or actual use of chemotherapy.

          -  Patients deprived of freedom or imprisoned patients with mental illnesses.

          -  Participant is part of another clinical trial or nutritional program.

          -  Hypogonadism diagnosis with not having received hormonal replacement previous to the
             study.

          -  Primary osteoporosis diagnosis.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Luz A González-Hernández, PhD</last_name>
    <phone>+52 3336147586</phone>
    <email>lagonzalez@hcg.gob.mx</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jaime F Andrade-Villanueva, MD</last_name>
    <phone>+52 3336145501</phone>
    <email>drjandradev@cucs.udg.mx</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Civil de Guadalajara Fray Antonio Alcalde</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44280</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aldo D Loza, MD</last_name>
      <phone>+52 3336147586</phone>
      <email>danielloza444@gmail.com</email>
    </contact>
    <investigator>
      <last_name>José R Barrientos-Ávila, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Francisco Ruiz-González, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>David E Carmona-Navarro, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Luz A González-Hernández, PhD MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jaime F Andrade-Villanueva, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Karina Sánchez-Reyes, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Monserrat Alvarez-Zavala, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <results_reference>
    <citation>Wheater G, Elshahaly M, Tuck SP, Datta HK, van Laar JM. The clinical utility of bone marker measurements in osteoporosis. J Transl Med. 2013 Aug 29;11:201. doi: 10.1186/1479-5876-11-201. Review.</citation>
    <PMID>23984630</PMID>
  </results_reference>
  <results_reference>
    <citation>Sattui SE, Saag KG. Fracture mortality: associations with epidemiology and osteoporosis treatment. Nat Rev Endocrinol. 2014 Oct;10(10):592-602. doi: 10.1038/nrendo.2014.125. Epub 2014 Aug 5. Review.</citation>
    <PMID>25091729</PMID>
  </results_reference>
  <results_reference>
    <citation>Rothman MS, Bessesen MT. HIV infection and osteoporosis: pathophysiology, diagnosis, and treatment options. Curr Osteoporos Rep. 2012 Dec;10(4):270-7. doi: 10.1007/s11914-012-0125-0. Review.</citation>
    <PMID>23100110</PMID>
  </results_reference>
  <results_reference>
    <citation>Panayiotopoulos A, Bhat N, Bhangoo A. Bone and vitamin D metabolism in HIV. Rev Endocr Metab Disord. 2013 Jun;14(2):119-25. doi: 10.1007/s11154-013-9246-8. Review.</citation>
    <PMID>23657562</PMID>
  </results_reference>
  <results_reference>
    <citation>Leal J, Gray AM, Prieto-Alhambra D, Arden NK, Cooper C, Javaid MK, Judge A; REFReSH study group. Impact of hip fracture on hospital care costs: a population-based study. Osteoporos Int. 2016 Feb;27(2):549-58. doi: 10.1007/s00198-015-3277-9. Epub 2015 Aug 19.</citation>
    <PMID>26286626</PMID>
  </results_reference>
  <results_reference>
    <citation>Compston J, Cooper A, Cooper C, Gittoes N, Gregson C, Harvey N, Hope S, Kanis JA, McCloskey EV, Poole KES, Reid DM, Selby P, Thompson F, Thurston A, Vine N; National Osteoporosis Guideline Group (NOGG). UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos. 2017 Dec;12(1):43. doi: 10.1007/s11657-017-0324-5. Epub 2017 Apr 19.</citation>
    <PMID>28425085</PMID>
  </results_reference>
  <results_reference>
    <citation>Bolland MJ, Grey AB, Horne AM, Briggs SE, Thomas MG, Ellis-Pegler RB, Woodhouse AF, Gamble GD, Reid IR. Annual zoledronate increases bone density in highly active antiretroviral therapy-treated human immunodeficiency virus-infected men: a randomized controlled trial. J Clin Endocrinol Metab. 2007 Apr;92(4):1283-8. Epub 2007 Jan 16.</citation>
    <PMID>17227801</PMID>
  </results_reference>
  <results_reference>
    <citation>Carlos F, Clark P, Maciel H, Tamayo JA. Direct costs of osteoporosis and hip fracture: an analysis for the Mexican Social Insurance Health Care System. Salud Publica Mex. 2009;51 Suppl 1:S108-13.</citation>
    <PMID>19287884</PMID>
  </results_reference>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>April 17, 2019</study_first_submitted>
  <study_first_submitted_qc>April 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 29, 2019</study_first_posted>
  <last_update_submitted>April 26, 2019</last_update_submitted>
  <last_update_submitted_qc>April 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Guadalajara</investigator_affiliation>
    <investigator_full_name>Luz Alicia González Hernández</investigator_full_name>
    <investigator_title>Head of HIV Unit in Hospital Civil de Guadalajara</investigator_title>
  </responsible_party>
  <keyword>4 mg zoledronic acid</keyword>
  <keyword>Colaren</keyword>
  <keyword>HIV</keyword>
  <keyword>Secondary Osteoporosis</keyword>
  <keyword>Man</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zoledronic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

